Novavax announced positive results from its pivotal Phase 3 trial of a combination influenza and COVID-19 vaccine. The trial met all primary endpoints, with strong efficacy and a favorable safety profile.
Novavax shares rose significantly in premarket and morning trading after the announcement. Analysts see the results as a potential catalyst for vaccine innovation and a future revenue stream. The findings may also give Novavax an advantage over some competitors developing combination vaccines.